BIOTRONIK announced today its partnership with AliveCor, a leading innovator in FDA-cleared personal electrocardiogram(ECG) technology and services. This partnership will combine the strengths of BIOTRONIK's BIOMONITOR Injectable Cardiac Monitor (designed with industry-leading 95.1% p-wave visibility1 across all cardiac cycles and 5.5-year longevity) with AliveCor's AI-enabled, clinically validated, medical-grade KardiaMobile 6L and KardiaMobile Card ECG technology. Through this pilot collaboration, healthcare providers will be able to access clinically relevant heart rhythm analyses and actionable reports to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and assessments to drive improvements in patient care and clinical outcomes.
Read more: New, smart, dissolving, and communicating pacemaker
Up to 25% of stroke patients present with AF2, the most common type of treated cardiac arrhythmia. Historically, screening options for early AF detection have been limited. Pairing AliveCor's KardiaMobile ECGs with BIOTRONIK's implantable device data strives to streamline workflow by providing comprehensive visibility within a single solution.
Until now, remote personal monitoring data and implantable device data have rarely been integrated, making it difficult for healthcare providers to access the full range of patient data. "Our FDA-cleared ECG technology paired with BIOTRONIK's implantable devices for cardiac rhythm diagnostics will allow a holistic view of the patient's heart health on the go while providing critical insights for physicians," said Vincent Balsamo, Executive Vice President of Global Sales at AliveCor, as a press release states.
"Connecting wearable and implantable cardiac diagnostic device data from the earliest stages in the care continuum is groundbreaking," said Kenneth Nelson, Head of Digital Health and Diagnostics at BIOTRONIK. "This pilot project intends to give physicians and caregivers a more longitudinal view of the patient's condition while simultaneously reducing the overall time spent on data management. We are proud to be on the frontier driving novel innovation."
This partnership aims to enable faster diagnosis, more informed clinical decision-making, and effective treatment by bringing complete information to every step in the diagnosis, device implant, and management process. Providing connected solutions with EHR-integrated monitoring may facilitate seamless sharing of secure ECG data to optimize physicians' workflow. "BIOTRONIK is pioneering a digital health ecosystem that is long overdue in the cardiac device industry," said Raul Weiss, MD, FHRS, FACC, Professor of Clinical Medicine, Cardiologist, Director, Electrophysiology Fellowship Program, Ohio State University Medical Center.
This pilot collaboration is the first in a series of partnerships with leading digital health organizations to improve the delivery of connected care in cardiac diagnostics and remote patient monitoring.
About BIOTRONIK
BIOTRONIK is a leading medical device company that has developed trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.
About AliveCor
AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies.
